Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease
{{output}}
Background: Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is an emerging device-aided therapy for advanced Parkinson's disease (PD), but real-world evidence on multidomain outcomes and treatment persistence... ...
